Factors Moving Markets: Complementary Research on GlaxoSmithKline, Cintas, Deere, Thermo Fisher and Pfizer

NEW YORK, December 19, 2014 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including GlaxoSmithKline (NYSE: GSK), Cintas (NASDAQ: CTAS), Deere (NYSE: DE), Thermo Fisher (NYSE: TMO), and Pfizer (NYSE: PFE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

GSK Research Report: ( http://get.analystsreview.com/pdf/?c=GlaxoSmithKline&d=19-Dec-2014&s=GSK ),

CTAS Research Report: ( http://get.analystsreview.com/pdf/?c=Cintas&d=19-Dec-2014&s=CTAS ),

DE Research Report: ( http://get.analystsreview.com/pdf/?c=Deere&d=19-Dec-2014&s=DE ),

TMO Research Report: ( http://get.analystsreview.com/pdf/?c=Thermo%20Fisher&d=19-Dec-2014&s=TMO ),

PFE Research Report: ( http://get.analystsreview.com/pdf/?c=Pfizer&d=19-Dec-2014&s=PFE ).

============

--

Analyst Update: Study Results, Quarterly Earnings, Divestment, and Credit Rating Update

Reviewed by: Rohit Tuli, CFA®

The U.S. stock market extended its winning streak on Thursday, recording its best two-day gains in last three years. The rally in U.S. started on Wednesday after Federal Reserve's Chairwoman Janet Yellen assured the markets that the central bank would be patient about lifting interest rate. The S&P 500 advanced 2.43%, Dow Jones Industrial Average moved up 2.40%, and Nasdaq Composite ended the session 2.24% up. The European stocks also surged, recording their strongest daily gain in three years, supported by a rise in Greek shares. The rebound in oil prices, dovish statement of Federal Reserve and calmness in Russian market also boosted European markets. Most Asian stock markets ended higher as investors were encouraged to take more risk following the positive stimulus led by the U.S. Federal Reserve statement.

GlaxoSmithKline plc (GlaxoSmithKline) announced that a pivotal phase III study to assess the efficacy of an investigational vaccine for the prevention of shingles, has met its primary endpoint, sending its ADRs up nearly 3% on Thursday. The vaccine, known as HZ/su, reduced the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo. Find out more about GlaxoSmithKline's investigational vaccine and analysts' views on the positive study results in our research report.

Cintas Corporation (Cintas) reported its second quarter fiscal 2015 results and surprised the street with better-than-expected growth in net income, driven by organic revenue growth as well as improved margin. Cintas also raised its FY 2015 earnings and sales guidance, citing improved U.S. economic conditions. Go to our research report on Cintas to view the Company's financial performance in detail.

Deere & Company (Deere) announced that it has agreed to sell its crop insurance business to West Des Moines, Iowa-headquartered Farmers Mutual Hail Insurance Company of Iowa (FMH). The move comes almost three months after the Company confirmed it was reviewing strategic options for the loss-making unit. Click on the report below to know more about Deere's move to exit the crop insurance business after 9 years.

Fitch Ratings has affirmed Thermo Fisher Scientific Inc.'s (Thermo Fisher) ratings, including the 'BBB' Issuer Default Rating (IDR). The Rating Outlook is revised to Stable from Negative. Shares of the Company increased 2.20% to close at $127.52. Find out what has triggered a revision in Thermo Fisher's rating outlook by clicking on the report below.

Pfizer Inc. (Pfizer) announced that a Phase 3 study evaluating its pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia showed statistically significant positive effect compared to placebo in the primary endpoint. Click on the report below to know more about Pfizer's latest study.

--

About Analysts Review

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED